Tekmira Presents Data on Hepatitis B Candidate TKM-HBV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 4:30PM CDT
Tekmira Pharmaceuticals Corporation (TKMR) presented encouraging preclinical data on its hepatitis B infection candidate, TKM-HBV.
MDVN: 92.54 (+2.91), AUXL: 30.35 (-0.06), LGND: 48.86 (+2.58), TKMR: 22.81 (-1.09)
Ebola Viral Infections Therapeutics Pipeline Review, H2 2014 Report - 23 Companies & 30+ Drug Profiles
M2 - Thu Oct 16, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mzj43q/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Tekmira Pharmaceuticals Corp. - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Toyama Chemical Co., Ltd. - Crucell N.V. - Medicago Inc. - NanoViricides, Inc. - BioCryst Pharmaceuticals, Inc. - Summit Corporation plc - AlphaVax, Inc. - Chimerix, Inc. - Microbiotix, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Vaxart, Inc. - Profectus BioSciences, Inc. - Navigen Pharmaceuticals, Inc. - Inhibikase Therapeutics, Inc. - Humabs BioMed SA - Mapp Biopharmaceutical, Inc. - NewLink Genetics Corporation - Epirus Biopharmaceuticals, Inc. Drug Profiles - Recombinant Vector Vaccine for Multivalent Filovirus - TKM-100802 - brincidofovir - favipiravir - Filovirus Vaccine - Drugs for Ebola and Marburg Infections - SMT-15000 - panfilovirus vaccine - BCX-4430 - ET-007 - ZMapp - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - ZMAb - MVA-BN-Filoviruses Vaccine - ebola virus vaccine - ebola and marburg vaccine (trivalent) - TKM-100701 - MMCatLMC - ebola and marburg rabies vaccine - Monoclonal Antibodies for Viral Infections - imatinib mesylate - oxocarbazate - thiocarbazate - EMER-IT - Ebola Vaccine - Synthetic Peptides for Ebola Virus - Monoclonal Antibodies for Ebola and Marburg Infections - ARD-5 - 1-E703 For more information visit http://www.researchandmarkets.com/research/mz...bola_viral
INO: 11.84 (+0.60), BCRX: 12.18 (+0.22), CMRX: 35.40 (+3.22), NLNK: 31.87 (+6.43), TKMR: 22.81 (-1.09), NNVC: 3.79 (+0.11), GSK: 42.88 (-0.25)
Tekmira Presents Results of Preclinical Studies With Hepatitis B Therapeutic
GlobeNewswire - Wed Oct 15, 2:30PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today the presentation of preclinical results characterizing TKM-HBV, a therapeutic agent targeting human hepatitis B virus (HBV), at the 10 Annual Meeting of the Oligonucleotide Therapeutics Society. Tekmira's Chief Technical Officer, Dr. Ian MacLachlan delivered a podium presentation titled, "Update on the Preclinical Development of an LNP-Based HBV Therapeutic." The conference is taking place in San Diego, California, from October 12 - 15, 2014.
TKMR: 22.81 (-1.09), TKM.TO: 25.58 (-1.12)
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver
PR Newswire - Wed Oct 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, TKMR, GILD, DDD and TASR.
TSLA: 226.35 (-3.35), GILD: 96.88 (+0.72), DDD: 40.90 (-0.37), TKMR: 22.81 (-1.09), TASR: 14.97 (+0.28)
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene
PR Newswire - Wed Oct 15, 8:10AM CDT
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Arrowhead Research Corporation (NASDAQ: ARWR), Chimerix Inc. (NASDAQ: CMRX), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, October 14, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,315.19, down 0.04% and the NASDAQ Composite closed at 4,227.17, up 0.32%. The S&P 500 finished the session 0.16% higher at 1,877.70. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 705.81, down 0.76%, whereas the index has advanced 9.89% on YTD basis. Register for your complimentary reports on these five stocks at:
CMRX: 35.40 (+3.22), ARWR: 7.02 (+0.55), IMGN: 8.38 (-0.38), TKMR: 22.81 (-1.09), CELG: 86.38 (-0.17)
Tekmira provides encouraging clinical data for LNP-Enabled Patisiran at the American Neurological Association's 2014 Annual Meeting
M2 - Tue Oct 14, 7:23AM CDT
Biopharmaceutical company Tekmira Pharmaceuticals (NasdaqCM:TKMR) (TSX:TKM.TO) pn Tuesday announced its six-month clinical data for the ongoing Patisiran Phase II Open Label Extension (OLE) study in patients with Familial Amyloidotic Polyneuropathy (FAP).
ALNY: 84.94 (+0.55), TKMR: 22.81 (-1.09)
Tekmira's Partner Reports Positive Clinical Data for LNP-Enabled Patisiran
GlobeNewswire - Mon Oct 13, 11:45PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension (OLE) study in patients with Familial Amyloidotic Polyneuropathy (FAP). Patisiran (ALN-TTR02) is an RNAi therapeutic targeting transthyretin (TTR) in development for the treatment of TTR-mediated amyloidosis (ATTR), which is enabled by Tekmira's lipid nanoparticle (LNP) technology.
ALNY: 84.94 (+0.55), TKMR: 22.81 (-1.09), TKM.TO: 25.58 (-1.12)
Is the U.S. Prepared to Handle Ebola?
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 12, 12:45PM CDT
Source: National Nurses United The passing of Eric Duncan, the first patient diagnosed with Ebola in the U.S., 10 days after being admitted to Texas Health Presbyterian Hospital, is a stark reminder of Ebola's insidious nature. It's a tough to...
CAH: 72.13 (-1.10), KMB: 105.04 (-0.37), TKMR: 22.81 (-1.09), SRCL: 117.12 (+0.97), GSK: 42.88 (-0.25), OMI: 32.24 (+0.06)
'Fast Money' Recap: How to Trade in a Volatile Marketplace
at The Street - Fri Oct 10, 4:00AM CDT
The trading panel discussed defensive trades, the state of the market and whether Carl Icahn is right about Apple.
TSLA: 226.35 (-3.35), LO: 58.00 (-0.72), XOM: 90.60 (+0.38), TKMR: 22.81 (-1.09), PANW: 97.88 (+0.45), TLT: 121.75 (-0.78), PEP: 90.79 (-0.98), T: 33.64 (-0.23), CMRX: 35.40 (+3.22), RIG: 30.15 (+0.71), AAL: 32.97 (+1.28), GOOGL: 536.92 (-3.81), TWTR: 48.23 (-1.76), AAPL: 96.26 (-1.28), AMZN: 302.86 (-3.11), FB: 72.63 (-0.58), SYMC: 22.03 (-0.12), TOT: 54.85 (-0.43), TSO: 59.81 (+1.17), CVEO: 12.40 (-0.31), IWM: 107.80 (+1.20), GPS: 36.49 (+0.55), CVX: 111.06 (+1.79), GG: 23.88 (+0.24)
Chimerix Falls as Ebola Patient on Brincidofovir Dies in US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 3:30PM CDT
Chimerix 's (CMRX) brincidofovir failed to save the Ebola patient.
MDVN: 92.54 (+2.91), BCRX: 12.18 (+0.22), CMRX: 35.40 (+3.22), TKMR: 22.81 (-1.09)
Hazmat Suit Maker Lakeland Soars On Dallas Ebola Fear
at Investor's Business Daily - Thu Oct 09, 1:38PM CDT
Lakeland Industries (LAKE) shares soared Thursday after a Dallas County sheriff's deputy was put in isolation with possible Ebola symptoms, raising fears the deadly virus may be spreading in the U.S. The company makes the ChemMax 1 hazmat suit, which...
CMRX: 35.40 (+3.22), HEB: 0.32 (-0.01), NLNK: 31.87 (+6.43), TKMR: 22.81 (-1.09), LAKE: 20.69 (-2.91), GSK: 42.88 (-0.25)
Tekmira to Present HBV Pre-Clinical Data at Meeting of the Oligonucleotide Therapeutics Society
GlobeNewswire - Thu Oct 09, 12:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Ian MacLachlan, Tekmira's Executive Vice President and Chief Technical Officer, will present preclinical data for TKM-HBV, the Company's product candidate targeting hepatitis B virus, at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society. The presentation will take place on Wednesday, October 15, 2014 at 12 pm (PT) / 3 pm (ET) in San Diego at The Hilton San Diego Resort and Spa.
TKMR: 22.81 (-1.09), TKM.TO: 25.58 (-1.12)
'Fast Money Halftime Report': U.S. Stocks Rebound, but Traders Look for a Pullback
at The Street - Wed Oct 08, 2:44PM CDT
The trading panel discusses energy and retail stocks, as well as whether the market has further downside ahead. GM CEO Mary Barra, a guest, talked about GM's future.
GPRO: 72.69 (-0.18), DFE: 48.16 (-0.50), F: 13.98 (+0.36), DUK: 78.17 (-0.73), GBX: 52.95 (+3.47), DAL: 33.32 (+0.94), TKMR: 22.81 (-1.09), DIS: 81.74 (-0.34), SMH: 46.42 (+0.55), SHLD: 30.00 (+0.44), CMRX: 35.40 (+3.22), SRPT: 22.30 (+1.39), TGT: 59.44 (-0.54), JCP: 7.30 (+0.21), COST: 122.95 (-1.35), GM: 29.94 (+0.25), LAKE: 20.69 (-2.91), XLE: 82.00 (+1.44)
Stock Market Today: Stocks Spike as Fed Minutes Allay Fears of Rate Hike
at The Street - Wed Oct 08, 1:24PM CDT
U.S. stocks popped on Wednesday after the release of the Federal Reserve minutes which allayed fears an interest rate hike could come sooner than expected.
ACT: 222.07 (+4.83), VRX: 118.54 (+4.20), MON: 110.66 (+1.83), VMW: 88.60 (-0.97), WMT: 73.82 (-1.38), TKMR: 22.81 (-1.09), SHLD: 30.00 (+0.44), AGN: 178.00 (+0.41), GTAT: 0.44 (+0.03), CMRX: 35.40 (+3.22), JCP: 7.30 (+0.21), EMC: 26.89 (-0.38), AAPL: 96.26 (-1.28), YUM: 67.62 (+0.39)
Ebola Outbreak Puts the Spotlight on 10 Biotech Companies
at The Street - Wed Oct 08, 11:32AM CDT
The Ebola outbreak has put the spotlight on Chimerix as well as other biotech companies with potential vaccines and even those stocks with marginal relation to the virus.
INO: 11.84 (+0.60), BCRX: 12.18 (+0.22), CMRX: 35.40 (+3.22), HEB: 0.32 (-0.01), SRPT: 22.30 (+1.39), NLNK: 31.87 (+6.43), TKMR: 22.81 (-1.09), LAKE: 20.69 (-2.91), GSK: 42.88 (-0.25)
Tekmira Pharmaceuticals (TKMR) Is Strong On High Volume Today
at The Street - Wed Oct 08, 10:35AM CDT
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a strong on high relative volume candidate
TKMR: 22.81 (-1.09)
The Disgusting Reaction to Ebola Patient's Death by Tekmira, Chimerix Traders
at The Street - Wed Oct 08, 10:33AM CDT
Tekmira shares surge after Thomas Duncan's death announced.
CMRX: 35.40 (+3.22), TKMR: 22.81 (-1.09)
Revised Guidance, Development Milestones, Appointment, Program Extension, and Event Schedules - Research Reports on Mylan, Tekmira, GSK, Cigna and WellPoint
PR Newswire - Wed Oct 08, 8:00AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), GlaxoSmithKline plc (NYSE: GSK), Cigna Corp. (NYSE: CI) and WellPoint Inc. (NYSE: WLP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7013-100free.
CI: 88.03 (-0.70), TKMR: 22.81 (-1.09), MYL: 48.77 (+1.39), GSK: 42.88 (-0.25), WLP: 111.92 (+0.86)
'Fast Money' Recap: What Should You Buy in a Declining Market?
at The Street - Wed Oct 08, 4:00AM CDT
The trading panel discusses Yum! Brands, the mining industry and Ebola treatments.
PEI: 19.46 (+0.31), CLR: 55.92 (+2.07), GMCR: 137.98 (-1.63), TKMR: 22.81 (-1.09), IBB: 260.98 (+4.51), M: 56.57 (+0.57), JBLU: 11.22 (+0.92), UPS: 95.63 (-0.82), PEP: 90.79 (-0.98), SBUX: 72.64 (+0.26), AGN: 178.00 (+0.41), SAVE: 55.66 (+1.69), CMRX: 35.40 (+3.22), EOG: 91.27 (+3.10), DPZ: 83.93 (+0.28), COST: 122.95 (-1.35), GOOGL: 536.92 (-3.81), CMLS: 3.57 (+0.28), AAPL: 96.26 (-1.28), MBLY: 46.46 (+1.11), YUM: 67.62 (+0.39), APC: 89.57 (+4.11), AMBA: 38.76 (+0.16), AEC: 18.52 (-0.09), GPRO: 72.69 (-0.18), ETN: 59.92 (+0.95), IR: 54.91 (+0.97), GSK: 42.88 (-0.25), PXD: 177.92 (+6.34), MCD: 89.91 (-0.53), GM: 29.94 (+0.25), IWM: 107.80 (+1.20), SODA: 21.09 (-0.12)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 07, 6:00PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TTS: 8.56 (-0.06), OLED: 29.86 (-0.22), EZPW: 9.55 (+0.16), CONN: 30.23 (+0.30), ADHD: 5.58 (+0.13), LINTB: 30.07 (+1.98), GWGH: 8.97 (+0.04), LINTA: 29.92 (+1.79), TKMR: 22.81 (-1.09), AEGN: 17.30 (+0.21), UCTT: 8.09 (unch), TKM.TO: 25.58 (-1.12)